# Harbour BioMed

Source: https://onco.cc/companies/harbour-biomed/  
OnCo record `harbour-biomed` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Harbour BioMed is a Hong Kong-listed antibody company, with operations in China, the Netherlands and the United States, whose fully human and heavy-chain-only antibody platforms feed cancer immunotherapy programmes and phase 3 trials.

## Summary

Harbour BioMed, founded in 2016 and listed in Hong Kong, owns the Harbour Mice transgenic platforms that produce fully human antibodies, including heavy-chain-only antibodies used for bispecifics. Its pipeline includes the anti-CTLA-4 antibody porustobart and the FcRn antibody batoclimab, and it licenses its platforms widely. ClinicalTrials.gov lists its Guangzhou company as lead sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Harbour BioMed (Guangzhou) Co. Ltd.; HBM
- Tags: ctgov-sponsor
- HQ: Rotterdam
- Type: biotech
- Website: https://www.harbourbiomed.com

## Sources

- Official website: https://www.harbourbiomed.com
- ClinicalTrials.gov: trials led by Harbour BioMed (Guangzhou) Co. Ltd.: https://clinicaltrials.gov/search?lead=Harbour%20BioMed%20(Guangzhou)%20Co.%20Ltd.
- Wikidata: https://www.wikidata.org/wiki/Q107517856

## Connected records

- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/harbour-biomed.json